Formulation and in vitro evaluation of cysteamine hydrochloride viscous solutions for the treatment of corneal cystinosis
- PMID: 18590953
- DOI: 10.1016/j.ejpb.2008.04.010
Formulation and in vitro evaluation of cysteamine hydrochloride viscous solutions for the treatment of corneal cystinosis
Abstract
In the present study, viscous solutions of cysteamine hydrochloride (CH) were prepared by using 0.5%, 1.0%, 1.5% or 3.0% of hydroxypropylmethylcellulose (HPMC) and were evaluated for their in-vitro characteristics and stability. Osmolalities, pH and viscosity of the formulations were determined. The influence of benzalkonium chloride and autoclave sterilization on solution characteristics was also investigated. For stability assessment, the viscous solutions were stored at +4 and +25 degrees C over 12 months. In-vitro characteristics and CH contents of the stored solutions were monitored. Irritation tests for the formulations were evaluated on rabbit eyes. Dialysis sac technique was used to perform in vitro release study of the solutions containing 1.0% and 1.5% HPMC. All of the viscous solutions tested showed non-newtonian (dilatant) flow behavior. Osmolality values were ranked between 351.2+/-6.2 and 355.1+/-7.9 mOsm kg(-1), and pH values were between 3.97+/-0.1 and 3.98+/-0.2 for all the solutions. Furthermore, no significant changes in dilatant behavior, osmolality or pH values of the pure HPMC solutions were observed. After addition of the excipients or CH-excipients, increased viscosity values were noted in these formulations. Neither benzalkonium chloride nor autoclave sterilization had any influence on viscosity, pH or osmolality values of the solution containing 1.5% HPMC. Stability studies showed that a faster decrease in the concentration of CH was observed in the formulations stored at 25 degrees C compared to those kept at 4 degrees C; no changes were determined in osmolality values of the solutions at all storage conditions. Increased pH and decreased viscosity values were noted in HPMC solutions containing CH and excipients, while no changes in these values were observed for pure HPMC solutions kept at 4 and 25 degrees C. In vitro release tests revealed that 81.2% and 85.3% of CH were released from the viscous solutions containing 1.5% and 1% HPMC, respectively, in 8h. No irritation was observed when the viscous solutions were tested on rabbit and human eyes.
Similar articles
-
Formulation, release characteristics and bioavailability of novel monolithic hydroxypropylmethylcellulose matrix tablets containing acetaminophen.J Control Release. 2005 Nov 28;108(2-3):351-61. doi: 10.1016/j.jconrel.2005.08.004. Epub 2005 Sep 12. J Control Release. 2005. PMID: 16154656 Clinical Trial.
-
Removal of corneal crystals by topical cysteamine in nephropathic cystinosis.N Engl J Med. 1987 Mar 26;316(13):775-9. doi: 10.1056/NEJM198703263161304. N Engl J Med. 1987. PMID: 3821824 Clinical Trial.
-
Effect of hydroxypropyl-beta-cyclodextrin on the solubility, stability and in-vitro release of ciprofloxacin for ocular drug delivery.Acta Pol Pharm. 2012 Jul-Aug;69(4):719-24. Acta Pol Pharm. 2012. PMID: 22876616
-
Efficacy and Safety of Topical Cysteamine in Corneal Cystinosis: A Systematic Review and Meta-Analysis.Am J Ophthalmol. 2021 Mar;223:275-285. doi: 10.1016/j.ajo.2020.07.052. Epub 2020 Sep 2. Am J Ophthalmol. 2021. PMID: 32888903
-
Evaluation of osmolality and pH of various concentrations of methotrexate, cytarabine, and thiotepa prepared in normal saline, sterile water for injection, and lactated Ringer's solution for intrathecal administration.J Oncol Pharm Pract. 2009 Mar;15(1):45-52. doi: 10.1177/1078155208096902. Epub 2008 Sep 4. J Oncol Pharm Pract. 2009. PMID: 18772215 Review.
Cited by
-
Microemulsions as Lipid Nanosystems Loaded into Thermoresponsive In Situ Microgels for Local Ocular Delivery of Prednisolone.Pharmaceutics. 2022 Sep 19;14(9):1975. doi: 10.3390/pharmaceutics14091975. Pharmaceutics. 2022. PMID: 36145726 Free PMC article.
-
Analysis of tear film in cystinosis patients treated with topical viscous cysteamine hydrochloride (Cystadrops®).Eur J Ophthalmol. 2022 Nov;32(6):3358-3362. doi: 10.1177/11206721221078649. Epub 2022 Feb 7. Eur J Ophthalmol. 2022. PMID: 35125035 Free PMC article.
-
Evaluation of topical cysteamine therapy in the CTNS(-/-) knockout mouse using in vivo confocal microscopy.Mol Vis. 2011;17:2649-54. Epub 2011 Oct 8. Mol Vis. 2011. PMID: 22065917 Free PMC article.
-
Cysteamine hydrochloride eye drop solution for the treatment of corneal cystine crystal deposits in patients with cystinosis: an evidence-based review.Clin Ophthalmol. 2018 Jan 24;12:227-236. doi: 10.2147/OPTH.S133516. eCollection 2018. Clin Ophthalmol. 2018. PMID: 29416314 Free PMC article. Review.
-
Cysteamine Eye Drops in Hyaluronic Acid Packaged in Innovative Single-Dose Systems, Part II: Long-Term Stability and Clinical Ocular Biopermanence.Pharmaceutics. 2023 Nov 5;15(11):2589. doi: 10.3390/pharmaceutics15112589. Pharmaceutics. 2023. PMID: 38004568 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical